Internal Medicine

In this interview, Dr. Wonder Drake shares physician resources and explains the unique presentation of sarcoidosis and how it varies by region.

The first controlled trial of the combination therapy shows its benefit in 6-week depressive symptom improvement versus lone bupropion.

A South Korea in-hospital assessment found that approximately half of all ordered CDI tests did not meet recommendation standards.

Investigators in a new multicenter study observed poor vaccine-induced serological responses in patients treated with infliximab or tofacitinib.

Developing research into the specific alterations of dysbiosis and diseases like arthritis suggest possibly novel pathways to therapy development.

New data suggest prediction of SARS-CoV-2 and bacterial co-infection or superinfection could be provided for hospitalized patients.

A Massachusetts General Hospital investigator explains how the innovative DCD practice addresses both waitlist issues and transplant center's capabilities.

Dr. Gerald Smetana encourages PCPs to familiarize themselves with the outpatient drug options for managing COVID-19 because of the limited treatment window for administration.

Expert psychiatrist Dr. Timothy Fong explains the complexity of using marijuana as treatment in a primary care setting and shares advice on how to address it with patients.

Patients who demonstrated high trough concentrations early on in treatment were more likely to achieve remission by weeks 14 or 52.

Subcutaneous administration of the gut-selective treatment was notably well-tolerated, safe, and cost-effective.

NAFLD is currently the most prevalent liver disease in the US.

An analysis of data from the KORA study suggests HSV 2 and CMV seropositivity were independently associated with increased odds of developing prediabetes.

An analysis of data from more than 3500 individuals followed for more than 20 years provides insight into the impact of food insecurity on risk of cardiometabolic conditions, including obesity and type 2 diabetes.

Massachusetts General Hospital surgery resident Selena S. Li, MD, discusses her overseas volunteer work caring for refugees escaping their home during the Russia invasion.

Investigators observed a potential risk between Black individuals with baseline signs of dehydration, SCT and related mortality over 30 years.

The daily oral combination therapy will be reconsidered for treating endometriosis pain this August.

The Massachusetts General Hospital investigator discusses how LVADs and mechanical circulatory supports have altered the national heart donor strategy.

Theresa R. Cerulli, MD, discusses the known clinical profile and evidential potential of the newest non-stimulant ADHD drug for adults.

Expert nephrologist Dr. Rajeev Raghavan elaborates on the American Diabetes Association guideline updates for patients with diabetic kidney disease during Pri-Med West.

Dr. Rajeev Raghavan talks about the role of SGLT2 inhibitors and GLP-1 receptor agonists as new therapeutics available to slow progression of chronic kidney disease.

Pri-Med West presenter Dr. Rajeev Raghavan highlights the key points of his nephrology talk and identifies trending topics in the field during an interview.

Data from a study presented at the European Congress on Obesity details the effects of adherence to a vegan diet on cardiometabolic health using data obtained from randomized controlled trials assessing the effects of vegan diets as an intervention.

An FDA decision could come as soon as this year. One expert stresses the need for improved screening, biomarker research, and patient communication beforehand.

Study author Arshad Khanani, MD, MA, discusses how the novel-targeting gene therapy candidate may uniquely benefit patients with treated retina disease.

A 3-month trial found reducing sedentary time by just an hour per day was enough to produce statistically significant changes in biomarkers for cardiovascular risk among patients with metabolic syndrome.

Veeral S. Sheth, MD, MBA, gives an update on his practice's adoption of the novel PDS in patients with AMD—and discusses other potential methods of anti-VEGF delivery.

Veeral S. Sheth, MD, MBA, discusses promising agents in development for geographic atrophy and other under-addressed ophthalmic diseases.

One researcher suggests the supplement may serve as an add-on measurement against AMD progression in early-stage patients.

An ARVO 2022 study author discusses her team's research into omega-3 fatty acids for diseases including dry AMD.